Stock Market Reviews

Read and share opinions on KZIA (Kazia Therapeutics Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
  Oct 7, 2025
• Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
  Oct 2, 2025
• Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
  Oct 1, 2025
• Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
  Sep 11, 2025
• Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
  Aug 1, 2025
• Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
  Jul 9, 2025
• Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
  Jul 9, 2025
• Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)
  Jun 13, 2025
• Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
  Jun 11, 2025
• Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
  Jun 5, 2025
• Kazia Therapeutics Highlights Recent Progress and Provides Business Update
  May 15, 2025
• Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
  Mar 31, 2025
• Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
  Feb 20, 2025
• Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?
  Jan 31, 2025
• Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
  Jan 30, 2025
• Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?
  Jan 27, 2025
• Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
  Jan 14, 2025
• Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
  Jan 11, 2025
• Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
  Jan 10, 2025